The CMSP has adopted the biocrates platform for quantitative MS-based metabolomics and lipidomics.  This unique platform utilizes a large panel of stable-isotope labeled internal standards that ensures accurate and reproducible identification and quantification of molecules indicative of metabolic activity. The approach overcomes the inherent challenges of untargeted MS-based metabolomics, improving reproducibility and addressing challenges in annotating detected compounds. It incorporates the accuracy, reproducibility, and compatibility to high-throughput analysis of large sample cohorts offered by targeted MS-based profiling, while still offering large-scale profiling of hundreds of molecules involved in central metabolic pathways, lipids and lipid-derived metabolites and small molecules relevant to metabolic disease.